Shares of TrovaGene are up 86c, or 23%, to $4.61 following the company’s report of new data from its ongoing Phase 1b/2 study evaluating onvansertib in combination with standard-of-care chemotherapy in Acute Myeloid Leukemia, or AML. Objective response rate has been observed at last 3 highest dose levels of onvansertib with 5 of 19 evaluable patients achieving a complete response, the company reported.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.